Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Clinical trial NCT05095376 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05095376
Sponsor: NRG Oncology
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Glioblastoma Gliosarcoma

Start date: 2022-03-28
Primary completion: 2026-02-12
Enrollment: 265

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.